Schonfeld Strategic Advisors LLC Purchases New Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

Schonfeld Strategic Advisors LLC purchased a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 20,382 shares of the company's stock, valued at approximately $524,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in NAMS. Jennison Associates LLC increased its position in shares of NewAmsterdam Pharma by 291.9% during the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after purchasing an additional 2,978,263 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of NewAmsterdam Pharma by 2,410.4% in the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock valued at $59,499,000 after acquiring an additional 2,222,900 shares during the period. Capital International Investors bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at $53,007,000. Alliancebernstein L.P. bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth approximately $47,752,000. Finally, Capital World Investors purchased a new position in NewAmsterdam Pharma in the fourth quarter worth $26,113,000. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Performance

NAMS traded down $0.47 during trading on Tuesday, hitting $18.75. 654,731 shares of the stock were exchanged, compared to its average volume of 624,382. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29. The firm has a 50 day simple moving average of $19.35 and a 200 day simple moving average of $21.24. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -9.97 and a beta of 0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to analysts' expectations of $1.46 million. As a group, equities analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Activity at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. This represents a 90.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James N. Topper bought 1,135 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the transaction, the director now directly owns 3,013,569 shares of the company's stock, valued at $67,775,166.81. This trade represents a 0.04% increase in their ownership of the stock. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently commented on NAMS. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Needham & Company LLC dropped their target price on NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Finally, Scotiabank lifted their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $43.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.